KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Bausch Health Companies (BHC) EBIT (2016 - 2025)

Historic EBIT for Bausch Health Companies (BHC) over the last 17 years, with Q3 2025 value amounting to $619.0 million.

  • Bausch Health Companies' EBIT rose 9465.41% to $619.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.9 billion, marking a year-over-year increase of 4051.85%. This contributed to the annual value of $1.5 billion for FY2024, which is 6054.0% up from last year.
  • Latest data reveals that Bausch Health Companies reported EBIT of $619.0 million as of Q3 2025, which was up 9465.41% from $444.0 million recorded in Q2 2025.
  • Bausch Health Companies' EBIT's 5-year high stood at $619.0 million during Q3 2025, with a 5-year trough of -$270.0 million in Q2 2021.
  • Moreover, its 5-year median value for EBIT was $285.0 million (2022), whereas its average is $250.1 million.
  • Data for Bausch Health Companies' EBIT shows a peak YoY increase of 744000.0% (in 2021) and a maximum YoY decrease of 90000.0% (in 2021) over the last 5 years.
  • Bausch Health Companies' EBIT (Quarter) stood at $367.0 million in 2021, then crashed by 164.31% to -$236.0 million in 2022, then skyrocketed by 253.39% to $362.0 million in 2023, then surged by 54.14% to $558.0 million in 2024, then increased by 10.93% to $619.0 million in 2025.
  • Its EBIT was $619.0 million in Q3 2025, compared to $444.0 million in Q2 2025 and $276.0 million in Q1 2025.